Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial
Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2015/259592 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559332868227072 |
|---|---|
| author | Shahrzad Shahidi Marziyeh Hoseinbalam Bijan Iraj Mojtaba Akbari |
| author_facet | Shahrzad Shahidi Marziyeh Hoseinbalam Bijan Iraj Mojtaba Akbari |
| author_sort | Shahrzad Shahidi |
| collection | DOAJ |
| description | Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done. |
| format | Article |
| id | doaj-art-1f3127bb8b944aa6817684552779e704 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-1f3127bb8b944aa6817684552779e7042025-02-03T01:30:15ZengWileyInternational Journal of Nephrology2090-214X2090-21582015-01-01201510.1155/2015/259592259592Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled TrialShahrzad Shahidi0Marziyeh Hoseinbalam1Bijan Iraj2Mojtaba Akbari3Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, IranIsfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, IranIsfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Epidemiology, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, IranBackground. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m2 in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done.http://dx.doi.org/10.1155/2015/259592 |
| spellingShingle | Shahrzad Shahidi Marziyeh Hoseinbalam Bijan Iraj Mojtaba Akbari Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial International Journal of Nephrology |
| title | Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |
| title_full | Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |
| title_fullStr | Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |
| title_full_unstemmed | Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |
| title_short | Effect of Pentoxifylline on Microalbuminuria in Diabetic Patients: A Randomized Controlled Trial |
| title_sort | effect of pentoxifylline on microalbuminuria in diabetic patients a randomized controlled trial |
| url | http://dx.doi.org/10.1155/2015/259592 |
| work_keys_str_mv | AT shahrzadshahidi effectofpentoxifyllineonmicroalbuminuriaindiabeticpatientsarandomizedcontrolledtrial AT marziyehhoseinbalam effectofpentoxifyllineonmicroalbuminuriaindiabeticpatientsarandomizedcontrolledtrial AT bijaniraj effectofpentoxifyllineonmicroalbuminuriaindiabeticpatientsarandomizedcontrolledtrial AT mojtabaakbari effectofpentoxifyllineonmicroalbuminuriaindiabeticpatientsarandomizedcontrolledtrial |